b. Chemistry panel 
c. T and B cell phenotype (as in 4.2.c) 
d. Lymphocyte proliferative responses (as in 4.2.d) 
e. Cellular ADA concentration 
f. Analysis for vector DNA, such as by semiquantitative PCR or Southern analysis. 
g. Bank serum for future analysis of Ig levels, antibody titers, etc. 
8.2 Evaluations at the End of Part 1 , Part 2.A. and Part 2.B. 
a. The tests listed under 8.1 above 
b. Skin test panel for DTH 
c. Immunoglobulin levels and isohemagglutinin titers 
d. Functional evaluation of B cell responsiveness and helper and suppressor T cell activity. 
e. Evaluations of NK, LAK, CML and anti-viral cytotoxic activity in PBL, as available. 
f. Immunization of the patient with an antigen such as Tetanus toxoid. Diphtheria toxoid, 
KLH, pneumovax, H. Influenza polysaccharide. Brucella abortus, 0X174, VEE or RVF; 
obtain weekly blood samples x4 for antibody titers 
g. PCR of blood lymphocytes for retroviral envelope 
h. Western blot analysis of serum for antibody to retroviral antigens 
8.3 Additional laboratory analyses during the course of treatment. 
a. Between the third and fourth ceil infusions of each Part, the patients will be immunized 
with a non-viable vaccine antigen to prime the peripheral lymphocyte pool obtained at 
the next phlebotomy to this new antigen. Following infusion of ADA gene-modified 
lymphocytes obtained after this immunization, we will carefully monitor the peripheral 
lymphocytes for antigen specific reactivity to this antigen including analysis of antigen 
induced proliferation, cytokine production, cytotoxicity, and antibody production as 
available. 
b. Studies of lymphocyte functional capacity including attempts to isolate alloantigen and 
neoantigen reactive clones and DTH to the neoantigen if available. 
8.4 Yearly follow-up laboratory evaluation. 
Recombinant DNA Research, Volume 14 
[233] 
